"We also know that the chemotherapy doesn't add much at all to these low-risk women - their outcomes are good", said Moore.
An analysis of a 2015 study of 249 patients found Omega-3 helped relieve symptoms among obese women taking the drug, who are more likely to experience joint pain.
For a while, doctors have suspected that not all patients needed to undergo chemotherapy treatments, but they were lacking the evidence to back up their claims. Women are given scores based on this test, classifying them as being either at high risk of recurrence, intermediate risk, or low risk. "You're never going to see these kinds of trials from the drug companies", because what is being tested might result in less use of their products, Brawley said.
Doctors say avoiding chemotherapy can spare women the high costs and side effects of the regimen.
The researchers found that the primary endpoint of the trial, invasive disease-free survival - the proportion of women who had not died or developed a recurrence or a second primary cancer - was very similar in both groups.
Dr. Jennifer Litton at MD Anderson Cancer Center in Houston, agreed, but said, "Risk to one person is not the same thing as risk to another". However, it is unclear if this benefit is due to the effect of chemotherapy or to endocrine suppression caused by chemotherapy-induced menopause. The test allows clinicians to assign a patient a recurrence score from 0 to 100. When the trial was activated, the best available genomic profiling data in women with early-stage breast cancer were retrospective. And while it doesn't officially wrap up until Tuesday afternoon, the confab's already produced a flurry of news on the latest in cancer drug development, from updates on immune therapy R&D to the promise (and, importantly, the limitations) of newfangled treatments for a growing number of cancers.
The study was funded by the National Cancer Institute, some foundations and proceeds from the USA breast cancer postage stamp.
Researchers share preliminary and more advanced results. In the old days we'd just have a bucket: 'breast cancer, ' 'prostate cancer, ' 'lung cancer.' Now we can look at the subtypes of cancer by looking at the genes and give the right treatment to the right patient at the right time.